Logo

Astellas Entered into an Exclusive License Agreement with Generian to Develop and Commercialize Novel Small Molecules for Undruggable Indications

Share this
Astellas Entered into an Exclusive License Agreement with Generian to Develop and Commercialize Novel Small Molecules for Undruggable Indications

Astellas Entered into an Exclusive License Agreement with Generian to Develop and Commercialize Novel Small Molecules for Undruggable Indications

Shots:

  • Generian to receive an upfront payment, ~$180M success-based milestone payments & royalties on global net sales of the newly developed products based on the proprietary drug discovery platform for indications with limited treatment options
  • Under the terms of the agreement, both companies will mutually conduct research & preclinical development activities to identify novel monovalent small molecules after which Astellas will be solely responsible for clinical development, manufacturing & commercialization of the products
  • Astellas will give the control of discovering small molecule therapies for treatment limited indications to Mitobridge acquired by Astellas on Jan’18

Ref: PR Newswire | Image: Generian

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions